Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

Sponsor

University of Virginia (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06009276

Collaborator

(none)

Enrollment

11.3

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle. This study is trying to find out if fitness status impacts the bacteria that are present in the oral microbiome (environment in the mouth) or the ability of the body to send blood to the skeletal muscle.

Participants will complete all or some of the following:

A mouth swab to assess the bacteria in their mouths.
Produce a saliva sample into a tube.
Cycle on a bike until you reach maximum effort.
Undergo blood draws
Wear a 24-hour non-invasive device that monitors blood pressure.
Undergo a test to assess blood flow to the muscles measured with an ultrasound.
Drink 70mL (1/3 of a cup) of concentrated beetroot juice once

Condition or Disease	Intervention/Treatment	Phase
Heart Failure, Systolic Heart Failure, Diastolic Peripheral Arterial Disease Overweight and Obesity

Detailed Description

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. Nitric oxide (NO) is a gaseous diatomic free-radical and is essential for a plethora of physiological functions involved in cardiometabolic health and CVD risk. NO bioavailability is associated with greater tissue perfusion, mitochondrial function, glucose regulation, and overall reduced CVD risk. The primary source of circulating NO is vascular endothelial nitric oxide synthase.

Unfortunately, the endothelium can be disrupted/damaged via a variety of CVD risk factors such as hypertension, smoking, hyperlipidemia, diabetes, inflammation, and hypercholesteremia. Disruption of the vascular endothelium and loss of bioavailable NO is a preliminary step in the progression of atherosclerosis and CVD. Decreased NO bioavailability and vascular dysfunction have been shown in a variety of clinical conditions including patients heart failure and peripheral artery disease (PAD).

Recently, an exogenous approach to increasing NO bioavailability via oral supplementation of inorganic nitrate (NO3-) has been utilized to increase NO bioavailability in various healthy and clinical populations. Briefly, inorganic NO3- is swallowed, absorbed into the circulation, and sequestered back into the salivary glands. NO3- is then secreted into the oral cavity, where bacteria containing nitrate reductase enzymes convert NO3- to nitrite (NO2-), which is again swallowed and absorbed into the circulation. NO2- in the plasma is then easily reduced to NO via non-enzymatic reactions.

This study aims to better elucidate the relationship between the oral microbiome abundance and diversity and NO3- to NO2- to NO conversion across a variety of subject populations ranging from healthy subjects to those with risk factors for CVD and people with diagnosed CVD. We also aim to examine the relationship between oral microbiome NO3- reduction and impaired skeletal muscle perfusion and exercise capacity as NO bioavailability plays a large role in these physiological processes.

The results of this study may allow us to better understand how novel interventions to modify the oral microbiome may improve cardiometabolic health and physical function in individuals with CVD and outline potential new therapeutic approaches.

The primary objective of this preliminary study is to compare the abundance and diversity of oral NO3- reducing bacteria in a variety of subjects with varying cardiometabolic health status and their ability to convert oral inorganic nitrate to nitrite measured in the saliva and plasma.

A secondary objective is to determine associations between the abundance and diversity of oral NO3- reducing bacteria and both skeletal muscle tissue perfusion during exercise and exercise capacity. A tertiary objective is to determine the stability of these relationships over time following lifestyle modifications (i.e., exercise, diet).

Study Design

Study Type:

Observational

Anticipated Enrollment :

70 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

Anticipated Study Start Date :

Aug 30, 2023

Anticipated Primary Completion Date :

Aug 7, 2024

Anticipated Study Completion Date :

Aug 7, 2024

Arms and Interventions

Arm	Intervention/Treatment
Heart Failure Patients diagnosed with Heart Failure (HFrEF and HFpEF). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
Peripheral Artery Disease Patients diagnosed with Peripheral Artery Disease (PAD). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.
Healthy Controls Individuals that are not diagnosed with cardiovascular disease. Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.

Outcome Measures

Primary Outcome Measures

Oral Nitrate Reducing Capacity [Baseline, 4-weeks, 12-weeks, 6-months]
Assessment of the oral microbiome's ability to reduce nitrate to nitrite. This will be measured through a swab on the dorsal surface of the tongue, an unstimulated saliva sample, and a rinse of a standard nitrate solution.

Secondary Outcome Measures

Skeletal muscle perfusion [Baseline, 4-weeks, 12-weeks, 6-months]
An I.V. will be placed and contrast ultrasound measurement of skeletal muscle blood flow of the calf, quad, and forearm at rest will be performed by the PI or a research sonographer using continuous infusion of Definity (2.3 mL diluted to 30 mL infused 1.5 ml/min) at a mechanical index (peak negative acoustic pressure/[frequency]) of 0.15 (defined by the American Society of Echocardiography contrast guidelines as low power).
Aerobic Capacity [Baseline, 4-weeks, 12-weeks, 6-months]
Peak aerobic capacity (VO2peak) will be assessed using a symptom-limited graded exercise test on a cycle ergometer.

Other Outcome Measures

Peripheral and Central Blood Pressures [Baseline, 4-weeks, 12-weeks, 6-months]
Brachial artery blood pressures will be obtained using a standard sphygmomanometer. Aortic blood pressures will be obtained using applanation tonometry (SphygmoCor version 8.0, AtCor Medical).
24-hour ambulatory blood pressure [Baseline, 4-weeks, 12-weeks, 6-months]
Blood pressure will be monitored using a standard ambulatory brachial artery blood pressure cuff (SunTech Oscar 2, SunTech Medical). Blood pressure measurements are programmed to be taken every 30-minutes during the day and every hour at night. This allows for monitoring of nighttime blood pressure changes and variations throughout the day.
Skeletal muscle microvascular perfusion (near-infra-red- spectroscopy) [Baseline, 4-weeks, 12-weeks, 6-months]
Tissue oxygenation will be captured noninvasively using non-invasive, near-infrared spectrometry (NIRS, PortaMon, Artinis Medical Systems B.V., The Netherlands) positioned on the gastrocnemius or vastus lateralis muscle.
Flow-Mediated Dilation [Baseline, 4-weeks, 12-weeks, 6-months]
Participants will be placed in a supine position with their left forearm slightly extended and supinated with legs straight. The arteries will be imaged using a high-resolution 7.5MHz linear array transducer at rest, during 5 minutes of forearm occlusion via cuff inflation, and continuously for 3 minutes post-occlusion; an EKG trigger will be used to capture images during end-diastole of the cardiac cycle.
Serum Glucose [Baseline, 4-weeks, 12-weeks, 6-months]
A blood sample will be obtained to measure serum glucose.
Insulin [Baseline, 4-weeks, 12-weeks, 6-months]
A blood sample will be obtained to measure insulin.
Lipids [Baseline, 4-weeks, 12-weeks, 6-months]
A blood sample will be obtained to measure lipids.
Hemoglobin [Baseline, 4-weeks, 12-weeks, 6-months]
A blood sample will be obtained to measure hemoglobin.
Hematocrit [Baseline, 4-weeks, 12-weeks, 6-months]
A blood sample will be obtained to measure hematocrit.
Plasma Nitrate [Baseline, 4-weeks, 12-weeks, 6-months]
A fasting blood draw will be taken. Following the blood draw, the participant will take one dose of Beetroot juice. The participant will then return to the lab three hours later for a second blood draw to assess level of nitrate in the plasma.
Plasma Nitrite [Baseline, 4-weeks, 12-weeks, 6-months]
A fasting blood draw will be taken. Following the blood draw, the participant will take one dose of Beetroot juice. The participant will then return to the lab three hours later for a second blood draw to assess level of nitrite in the plasma.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
Subjects may be of either sex with age 18 years.

Exclusion Criteria:

Oral antibiotic use within previous four weeks
Oral disease or poor oral health as determined by the Oral Health Questionnaire
Using an antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use
Tobacco smokers
Pregnant or lactating females
Hypersensitivity to any ultrasound contrast agent
Inability to perform exercise
Unable to communicate effectively in English to the study team.
Diagnosis of chronic renal failure (GFR < 60 ml/min/1.73m)
Subjects taking nitroglycerine (or inorganic nitrates), PDE-5 inhibitors (ex: Cialis, Viagra), and xanthine oxidase inhibitors (ex: Allopurinol).